OlsAro

GigaCrop is a Berkeley, California agricultural biotech company that uses enzyme engineering and machine learning to design new carbon-fixation enzymes and pathways that bypass Rubisco, aiming to up to double yields of crops such as corn and soy and improve drought tolerance.

Anew Labs is an AI-driven drug discovery company spun out of ByteDance. Its team was formed inside ByteDance in 2021 by Liu Kai and was spun off as an independent company in June 2026, headquartered in Yangpu, Shanghai, with offices in the US and Singapore. It builds AI drug-discovery platforms (AnewFold, AnewSampling, AnewOmni, AnewDesign, AnewMind) spanning protein structure prediction, all-atom molecular generation, antibody design and scientific reasoning, with a pipeline of preclinical candidates including a small-molecule inhibitor targeting IL-17 family dimers.

Insilico Medicine, founded in 2019 in Shanghai, China, is a developer of drug candidates for anti-aging and cancer treatment.

Biographica, founded in 2022 in London, UK, uses machine learning to identify crop gene-editing targets and accelerate breeding research and development.

Manas AI, founded in 2025 in New York, USA, uses AI to accelerate the discovery and development of new drugs, with an initial focus on aggressive cancers such as breast cancer, prostate cancer, and lymphoma.

Network Bio is a Palo Alto, California biotechnology company founded in 2022 that builds disease-specific AI models from human biological data. Its vertically integrated platform combines a biological research network that sources, links and structures tissue, blood and longitudinal clinical outcomes from leading U.S. academic medical centers (Mass General Brigham, University of Pennsylvania, Duke University, University of Colorado Anschutz and UCSF, spanning 500,000+ patients across oncology, immunology, metabolic and cardiovascular disease) into AI-ready datasets, with a bio-native AI architecture purpose-built to learn from multimodal biological data, overcome technical confounders and batch effects, and generate interpretable representations of disease biology that generalize across diseases, tissues and modalities.